ArticleJournal of experimental & clinical cancer research : CR2019

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.

Silvia La Monica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.